Intellia Therapeutics Inc Asset Resilience Ratio

Latest as of December 2025: 34.96%

Intellia Therapeutics Inc asset resilience ratio. Intellia Therapeutics Inc (NTLA) has an Asset Resilience Ratio of 34.96% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NTLA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$294.42 Million

Cash + Short-term Investments

Total Assets

$842.13 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Intellia Therapeutics Inc (2016–2025)

Asset resilience ratio of Intellia Therapeutics Inc from 2016 to 2025. This chart shows how Intellia Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Intellia Therapeutics Inc (NTLA) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Intellia Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NTLA total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$294.42 Million	34.96%
Total Liquid Assets	$294.42 Million	34.96%

Asset Resilience Insights

Very High Liquidity: Intellia Therapeutics Inc maintains exceptional liquid asset reserves at 34.96% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Intellia Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Intellia Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Intellia Therapeutics Inc Asset Resilience Ratio by Year (2016–2025)

Intellia Therapeutics Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Intellia Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	34.96%	$294.42 Million	$842.13 Million	+0.34pp
2024-12-31	34.62%	$412.33 Million	$1.19 Billion	-18.07pp
2023-12-31	52.69%	$685.48 Million	$1.30 Billion	+8.67pp
2022-12-31	44.02%	$669.12 Million	$1.52 Billion	-4.29pp
2021-12-31	48.30%	$625.28 Million	$1.29 Billion	-16.36pp
2020-12-31	64.67%	$437.35 Million	$676.32 Million	-1.89pp
2019-12-31	66.56%	$222.50 Million	$334.28 Million	-6.92pp
2018-12-31	73.48%	$255.20 Million	$347.31 Million	--
2017-12-31	0.00%	$0.00	$376.24 Million	--
2016-12-31	0.00%	$0.00	$298.97 Million	--

pp = percentage points

About Intellia Therapeutics Inc

NASDAQ:NTLA USA Biotechnology

Market Cap

$1.45 Billion

Market Cap Rank

#7113 Global

#2197 in USA

Share Price

$12.31

Change (1 day)

+3.79%

52-Week Range

$8.04 - $17.84

All Time High

$176.78